anti-CD39 antibody

An anti-CD39 antibody is a type of monoclonal antibody designed to target and inhibit ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1), commonly known as CD39. CD39 is an enzyme highly expressed in the tumor microenvironment (TME) on both tumor cells and immune cells (such as regulatory T cells and myeloid-derived suppressor cells). It initiates the adenosinergic pathway by hydrolyzing extracellular adenosine triphosphate (eATP) and adenosine diphosphate (ADP) into adenosine monophosphate (AMP), which is subsequently converted to immunosuppressive adenosine by CD73. By blocking CD39, anti-CD39 antibodies prevent the accumulation of immunosuppressive adenosine and preserve immunostimulatory eATP levels, thereby promoting a pro-inflammatory tumor microenvironment and enhancing anti-tumor immune responses. Several anti-CD39 antibodies, such as TTX-030, IPH5201, and SRF617, have been developed and evaluated in clinical trials for various solid tumors.

Other names

CD39 antibodyCD-39 antibodyCD 39 antibodyCD39 inhibitor antibodyCD-39 inhibitor antibodyCD 39 inhibitor antibodyanti-CD39 monoclonal antibodyanti-CD-39 monoclonal antibodyanti-CD 39 monoclonal antibody